Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNA11 | P29992 | 8/20 | 0.85 |
| ▸ | GNAQ | P50148 | 3/20 | 0.85 |
| ▸ | ELANE | P08246 | 4/20 | 0.33 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22133305 | 0.95 | GNA11 (0.90) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL22133302 | 0.93 | GNA11 (0.86) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL22133481 | 0.93 | GNA11 (0.85) | GNA11GNAQELANE | |
| SCHEMBL22139582 | 0.92 | GNA11 (0.85) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL29587750 | 0.92 | GNA11 (0.93) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL13820269 | 0.92 | GNA11 (1.00) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL14361129 | 0.92 | GNA11 (1.00) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL26118416 | 0.92 | GNA11 (1.00) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL22139577 | 0.89 | GNA11 (0.80) | GNA11GNAQELANEHTRA1 | |
| SCHEMBL29802053 | 0.89 | GNA11 (0.84) | GNA11GNAQELANEHTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| WO-2020128612-A2 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | GNA15, GNA11, EEA1 | GNA11 2/4885GNAQ 4/4885ELANE 1843/4885 |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | GNA15, GNA11, EEA1 | GNA11 2/4885GNAQ 5/4885ELANE 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.